35 hours ago Portal for MicroGen DX - Patient Portal. If you dont have an account Register here Register here >> Go To The Portal
Our Billing Department is available for any questions or concerns regarding your MicroGenDX bill at at 1-855-208-0019 option #2. The Billing Department is open 8AM to 5PM CST Monday through Friday. Please call the phone number on the back of your insurance card for information on coverage of any MicroGenDX test.
The laboratory utilizes molecular diagnostics and specializes in Next Generation DNA Sequencing technologies to identify pathogenic microbes within patient samples. MicroGenDX® is currently licensed to provide these services in 49 of the 50 states, with New York being the exception.
Southwest Regional PCR first offered a 2-step process combining qPCR and NGS to identify microbes in 2010 under the commercial name PathoGenius. In 2017, the laboratory was purchased by Rick Martin, head of commercialization for this testing, and rebranded as Southwest Regional PCR dba MicroGenDX.
For information regarding coverage and benefits from your insurance carrier, please contact your insurance carrier directly. Information about how a specific claim is processed should be provided to you from your insurance carrier on an Explanation of Benefits (EOB) form. These forms usually differ with each insurance carrier. You can click here for a uniform glossary of terms, which may help you interpret the information provided by your insurance carrier.
Medicare provides a "crossover" program that automatically forwards patients claims to their secondary insurance carrier for coordination of benefits. To take advantage of this program, please contact Medicare directly to notify them of your secondary insurance coverage.
You can provide your insurance information directly to MicroGenDX by calling our Billing Department at 855-208-0019 option #2. Please be sure that the information provided is accurate and complete. Inaccurate or incomplete information may result in a delay or denial of payment by your insurance carrier. You can also mail or fax a copy of the front and back of your insurance card to the correspondence address or fax number listed on your invoice.
It typically takes about four to six weeks for your insurance carrier to process your claim and send you and Explanation of Benefits (EOB).
Our Billing Department is available for any questions or concerns regarding your MicroGenDX bill at at 1-855-208-0019 option #2. The Billing Department is open 8AM to 5PM CST Monday through Friday.
The invoice you received is for laboratory services provided by MicroGenDX, which were ordered by your physician. This invoice is for laboratory testing fees only and is separate from any bill you may have received from your physician and/or paid at your physicians office.
Contact the Billing Department at 1-855-208-0019 option #2 with additional questions or to begin a payment plan.
MicroGenDX laboratory has run over 500,000 next-gen DNA sequencing tests at our state-of-the-art, CAP-accredited, CLIA-licensed molecular diagnostic facility. Our advanced instrumentation, including Illumina Miseq sequencers, provides the industry’s most informative microbial diagnostics for ENT/AFB, microbiology laboratories, orthopedics, urology, wound care, podiatry, pulmonary, ExPlants, periodontal, podiatry/nail, OB-GYN, infectious disease, and other medical specialties. Our laboratory is supported by a team of molecular biologists, biochemists, bioinformaticians, computer scientists, and physicians. MicroGenDX employs over 200 passionate employees, with a leadership model that swiftly adapts to global health concerns and new technologies. We want to help as many people as possible with microbial identification of challenging infections.
We increased laboratory capacity in response to the pandemic, allowing us to run over 5,000 samples per day. Our rapid COVID-19 PCR test is FDA EUA approved and has a 24-hour turnaround from the time of sample receipt.
Our mission at MicroGenDX is to improve clinical outcomes by offering clinicians and their patients the most informative and impactful microbial diagnostic tests that science can provide .
Southwest Regional PCR first offered a 2-step process combining qPCR and NGS to identify microbes in 2010 under the commercial name PathoGenius. In 2017, the laboratory was purchased by Rick Martin, head of commercialization for this testing, and rebranded as Southwest Regional PCR dba MicroGenDX. Since that new branding and leadership, the laboratory has grown in scale and reach for physicians, specialties and infection types – both nationally and internationally.
Founded by an esteemed wound care doctor Randall Wolcott in 2008, and currently owned and operated by Rick Martin, a former Pfizer executive , who personally witnessed the positive clinical impact of qPCR+NGS, MicrogenDX is bringing state-of-the-art microbial DNA sequencing diagnostics to more patients every day – processing more than 100,000 samples each year.
Level 1 test for Bactrim is a real-time quantitative PCR assay utilizing the Roche LightCycler 480 . This taqman assay uses dye labelled hydrolysis probes to detect the presence of a unique sequence in the sul I and sul II genes specific to Bactrim resistance. Sulfonamides and TMP target two enzymes, dihydropteroate synthetase or DHPS and dihydrofolate reductase or DHFR, to disrupt steps in the folic acid production cycle by inhibiting the production of dihydrofolic acid and tetrahydrofolic acid. Transferable resistance to bactrim is mediated by two drug-resistant DHPS enzymes, which are encoded in sul I and sul II genes. The accuracy, sensitivity, and specificity of the qPCR assay are 100%. The limit of detection is 0.004ng/uL.
Level 1 test for Tetracycline resistance is a real-time qualitative PCR assay utilizing the Roche LightCycler 480. This taqman assay uses dye labeled hydrolysis probes to detect the presence of a unique sequence in the tetM and tetB gene specific to tetracycline resistance. Tetracycline resistance occurs when proteins stop binding the tetracycline to the bacterial ribosome. There are 14 proteins that can block the binding site, but four cause the majority of blockage. The most common protein found is tetM (at 80%). The proteins tetA and tetB were identified first, but their mechanism is utilized in many of the same bacteria (10%). The protein tetO is the newest discovered at less than 5% and many identified outside the USA. The other 10 proteins make up the remaining 5%. The accuracy, sensitivity, and specificity of the qPCR assay are 100%. The limit of detection is 0.014ng/uL.
Level 1 test for vancomycin resistance is a real-time qualitative PCR assay utilizing the Roche LightCycler 480. This taqman assay uses dye labeled hydrolysis probes to detect the presence of a unique sequence in the vanA genes specific to vancomycin resistance. The vanA gene is the most common mutated gene used to detect vancomycin resistance. The accuracy, sensitivity, and specificity of the qPCR assay are 100%. The limit of detection is 0.0005ng/uL.
Qnr is a common quinolone resistance gene that blocks the quinolone antibiotics from inhibiting the DNA gyrase activity. A mutation in the DNA gyrase subunit A, gyrA, causes the quinolone antibiotics to become ineffective at stopping the DNA gyrase replication.
Level 1 test for Quinolone resistance is a real-time qualitative PCR assay utilizing the Roche LightCycler 480. This taqman assay uses dye labeled hydrolysis probes to detect the presence of a unique sequence in the qnr and gyrA gene specific to quinolone resistance. Quinolone antibiotics inhibit bacterial replication by stabilizing the complex between DNA and DNA gyrase or topoisomerase and blocking the polymerase from binding during replication. Quinolone resistance occurs when the DNA gyrase or topoisomerase is protected against the cleaving caused by Quinolone antibiotics. Qnr is a common quinolone resistance gene that blocks the quinolone antibiotics from inhibiting the DNA gyrase activity. A mutation in the DNA gyrase subunit A, gyrA, causes the quinolone antibiotics to become ineffective at stopping the DNA gyrase replication. The accuracy, sensitivity, and specificity of the qPCR assay are 100%. The limit of detection is 0.001ng/uL.
Quinolone antibiotics inhibit bacterial replication by stabilizing the complex between DNA and DNA gyrase or topoisomerase and blocking the polymerase from binding during replication . Quinolone resistance occurs when the DNA gyrase or topoisomerase is protected against the cleaving caused by Quinolone antibiotics.
The mecA gene is the most common gene used to detect methicillin resistance among Staphylococcus species. The accuracy, sensitivity, and specificity of the qPCR assay are 98.9%, 100%, and 95.2%. The limit of detection is 0.0147ng/uL. Vancomycin Level 1: